{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Phosphotransferases phosphomutases : Questions médicales les plus fréquentes",
"headline": "Phosphotransferases phosphomutases : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Phosphotransferases phosphomutases : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-06-08",
"dateModified": "2025-03-05",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Phosphotransferases phosphomutases"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Intramolecular transferases",
"url": "https://questionsmedicales.fr/mesh/D019751",
"about": {
"@type": "MedicalCondition",
"name": "Intramolecular transferases",
"code": {
"@type": "MedicalCode",
"code": "D019751",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D08.811.399.520"
}
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Bisphosphoglycerate mutase",
"alternateName": "Bisphosphoglycerate Mutase",
"url": "https://questionsmedicales.fr/mesh/D001731",
"about": {
"@type": "MedicalCondition",
"name": "Bisphosphoglycerate mutase",
"code": {
"@type": "MedicalCode",
"code": "D001731",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D08.811.399.520.750.250"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Phosphoglucomutase",
"alternateName": "Phosphoglucomutase",
"url": "https://questionsmedicales.fr/mesh/D010733",
"about": {
"@type": "MedicalCondition",
"name": "Phosphoglucomutase",
"code": {
"@type": "MedicalCode",
"code": "D010733",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D08.811.399.520.750.625"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Phosphoglyceromutase",
"alternateName": "Phosphoglycerate Mutase",
"url": "https://questionsmedicales.fr/mesh/D010736",
"about": {
"@type": "MedicalCondition",
"name": "Phosphoglyceromutase",
"code": {
"@type": "MedicalCode",
"code": "D010736",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D08.811.399.520.750.700"
}
}
}
],
"about": {
"@type": "MedicalCondition",
"name": "Phosphotransferases phosphomutases",
"alternateName": "Phosphotransferases (Phosphomutases)",
"code": {
"@type": "MedicalCode",
"code": "D017875",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Stewart Shuman",
"url": "https://questionsmedicales.fr/author/Stewart%20Shuman",
"affiliation": {
"@type": "Organization",
"name": "Molecular Biology Program, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA shumans@mskcc.org."
}
},
{
"@type": "Person",
"name": "Jean-Marc Jeckelmann",
"url": "https://questionsmedicales.fr/author/Jean-Marc%20Jeckelmann",
"affiliation": {
"@type": "Organization",
"name": "Institute of Biochemistry and Molecular Medicine, Medical Faculty, University of Bern, Bern, Switzerland."
}
},
{
"@type": "Person",
"name": "Balraj Doray",
"url": "https://questionsmedicales.fr/author/Balraj%20Doray",
"affiliation": {
"@type": "Organization",
"name": "Department of Internal Medicine, Washington University School of Medicine, St. Louis, MO, USA."
}
},
{
"@type": "Person",
"name": "Benjamin C Jennings",
"url": "https://questionsmedicales.fr/author/Benjamin%20C%20Jennings",
"affiliation": {
"@type": "Organization",
"name": "Department of Internal Medicine, Washington University School of Medicine, St. Louis, MO, USA."
}
},
{
"@type": "Person",
"name": "Wang-Sik Lee",
"url": "https://questionsmedicales.fr/author/Wang-Sik%20Lee",
"affiliation": {
"@type": "Organization",
"name": "Department of Internal Medicine, Washington University School of Medicine, St. Louis, MO, USA."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "How does community health feature in Global Financing Facility planning documents to support reproductive, maternal, newborn, child and adolescent health and nutrition (RMNAH-N)? insights from six francophone West African countries.",
"datePublished": "2024-10-02",
"url": "https://questionsmedicales.fr/article/39354843",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1080/16549716.2024.2407680"
}
},
{
"@type": "ScholarlyArticle",
"name": "Comparison of Cranial Cruciate Ligament Rupture Incidence among Parous and Nulliparous Rottweiler Bitches: Evidence from a Lifetime Cohort Study Supporting a Paradigm of Pregnancy-Associated Protection against Subsequent Non-Reproductive Disease Outcomes.",
"datePublished": "2024-09-07",
"url": "https://questionsmedicales.fr/article/39272393",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3390/ani14172608"
}
},
{
"@type": "ScholarlyArticle",
"name": "Factors associated with use of community-based, peer-led sexual and reproductive health services by adolescent boys and young men aged 18-24 in Lusaka, Zambia: A case control study nested in the Yathu Yathu trial.",
"datePublished": "2023-11-14",
"url": "https://questionsmedicales.fr/article/37963113",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1371/journal.pgph.0002446"
}
},
{
"@type": "ScholarlyArticle",
"name": "Reproduction toxicity study with the synthetic amorphous silica SYLOID® AL-1 FP, HDK® N20, LUDOX® P T-40F and SYLOID® MX 107 in the earthworm species Eisenia fetida.",
"datePublished": "2024-05-03",
"url": "https://questionsmedicales.fr/article/38705261",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.toxlet.2024.04.011"
}
},
{
"@type": "ScholarlyArticle",
"name": "Evaluation of the relations between reproduction-related pituitary and ovarian hormones and abdominal fat area-related variables determined with computed tomography in overweight or obese women who have undergone bariatric surgery: a cross-sectional study.",
"datePublished": "2023-09-14",
"url": "https://questionsmedicales.fr/article/37869350",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.21037/qims-22-1283"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Enzymes et coenzymes",
"item": "https://questionsmedicales.fr/mesh/D045762"
},
{
"@type": "ListItem",
"position": 3,
"name": "Enzymes",
"item": "https://questionsmedicales.fr/mesh/D004798"
},
{
"@type": "ListItem",
"position": 4,
"name": "Isomerases",
"item": "https://questionsmedicales.fr/mesh/D007535"
},
{
"@type": "ListItem",
"position": 5,
"name": "Intramolecular transferases",
"item": "https://questionsmedicales.fr/mesh/D019751"
},
{
"@type": "ListItem",
"position": 6,
"name": "Phosphotransferases phosphomutases",
"item": "https://questionsmedicales.fr/mesh/D017875"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Phosphotransferases phosphomutases - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Phosphotransferases phosphomutases",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-13",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Phosphotransferases phosphomutases",
"description": "Comment diagnostiquer une déficience en phosphomutases ?\nQuels tests sont utilisés pour évaluer l'activité des phosphomutases ?\nQuels symptômes peuvent indiquer un problème avec les phosphomutases ?\nLes tests génétiques sont-ils utiles pour le diagnostic ?\nQuelle imagerie peut aider à diagnostiquer des troubles liés aux phosphomutases ?",
"url": "https://questionsmedicales.fr/mesh/D017875?mesh_terms=Reproduction&page=729#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Phosphotransferases phosphomutases",
"description": "Quels sont les symptômes d'une déficience en phosphomutases ?\nLes douleurs musculaires sont-elles liées aux phosphomutases ?\nPeut-on observer des anomalies métaboliques ?\nLes symptômes varient-ils selon l'âge ?\nY a-t-il des signes cliniques spécifiques à surveiller ?",
"url": "https://questionsmedicales.fr/mesh/D017875?mesh_terms=Reproduction&page=729#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Phosphotransferases phosphomutases",
"description": "Peut-on prévenir les troubles liés aux phosphomutases ?\nY a-t-il des conseils diététiques pour prévenir les symptômes ?\nLes tests de dépistage sont-ils recommandés ?\nComment le suivi médical aide-t-il à la prévention ?\nLes vaccinations ont-elles un rôle dans la prévention ?",
"url": "https://questionsmedicales.fr/mesh/D017875?mesh_terms=Reproduction&page=729#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Phosphotransferases phosphomutases",
"description": "Quels traitements sont disponibles pour les troubles liés aux phosphomutases ?\nLa thérapie génique est-elle une option ?\nLes médicaments peuvent-ils aider à gérer les symptômes ?\nY a-t-il des traitements expérimentaux en cours ?\nComment la nutrition influence-t-elle le traitement ?",
"url": "https://questionsmedicales.fr/mesh/D017875?mesh_terms=Reproduction&page=729#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Phosphotransferases phosphomutases",
"description": "Quelles complications peuvent survenir avec une déficience en phosphomutases ?\nLes complications sont-elles réversibles ?\nComment les complications affectent-elles la qualité de vie ?\nY a-t-il des risques de complications à long terme ?\nLes complications peuvent-elles être prévenues ?",
"url": "https://questionsmedicales.fr/mesh/D017875?mesh_terms=Reproduction&page=729#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Phosphotransferases phosphomutases",
"description": "Quels sont les facteurs de risque pour les troubles des phosphomutases ?\nL'environnement joue-t-il un rôle dans ces troubles ?\nLes habitudes alimentaires influencent-elles le risque ?\nY a-t-il des groupes à risque spécifique ?\nLe stress peut-il affecter le risque de troubles ?",
"url": "https://questionsmedicales.fr/mesh/D017875?mesh_terms=Reproduction&page=729#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer une déficience en phosphomutases ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests enzymatiques et des analyses biochimiques sont utilisés pour diagnostiquer."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour évaluer l'activité des phosphomutases ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les tests d'activité enzymatique in vitro mesurent la fonction des phosphomutases."
}
},
{
"@type": "Question",
"name": "Quels symptômes peuvent indiquer un problème avec les phosphomutases ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des troubles métaboliques, fatigue et douleurs musculaires peuvent survenir."
}
},
{
"@type": "Question",
"name": "Les tests génétiques sont-ils utiles pour le diagnostic ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, ils peuvent identifier des mutations spécifiques liées aux phosphomutases."
}
},
{
"@type": "Question",
"name": "Quelle imagerie peut aider à diagnostiquer des troubles liés aux phosphomutases ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'imagerie par résonance magnétique (IRM) peut être utilisée pour évaluer les tissus."
}
},
{
"@type": "Question",
"name": "Quels sont les symptômes d'une déficience en phosphomutases ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes incluent fatigue, faiblesse musculaire et troubles de la croissance."
}
},
{
"@type": "Question",
"name": "Les douleurs musculaires sont-elles liées aux phosphomutases ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des douleurs musculaires peuvent survenir en raison de troubles métaboliques."
}
},
{
"@type": "Question",
"name": "Peut-on observer des anomalies métaboliques ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des anomalies dans le métabolisme des glucides et des lipides peuvent être présentes."
}
},
{
"@type": "Question",
"name": "Les symptômes varient-ils selon l'âge ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les symptômes peuvent se manifester différemment selon l'âge et le développement."
}
},
{
"@type": "Question",
"name": "Y a-t-il des signes cliniques spécifiques à surveiller ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des signes comme l'hypoglycémie et des troubles neurologiques peuvent être observés."
}
},
{
"@type": "Question",
"name": "Peut-on prévenir les troubles liés aux phosphomutases ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "La prévention est difficile, mais un diagnostic précoce peut aider à gérer les symptômes."
}
},
{
"@type": "Question",
"name": "Y a-t-il des conseils diététiques pour prévenir les symptômes ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une alimentation équilibrée et riche en nutriments peut aider à prévenir certains symptômes."
}
},
{
"@type": "Question",
"name": "Les tests de dépistage sont-ils recommandés ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests de dépistage peuvent être recommandés pour les familles à risque."
}
},
{
"@type": "Question",
"name": "Comment le suivi médical aide-t-il à la prévention ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un suivi médical régulier permet de surveiller les symptômes et d'ajuster le traitement."
}
},
{
"@type": "Question",
"name": "Les vaccinations ont-elles un rôle dans la prévention ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les vaccinations ne préviennent pas directement les troubles enzymatiques, mais aident à la santé générale."
}
},
{
"@type": "Question",
"name": "Quels traitements sont disponibles pour les troubles liés aux phosphomutases ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le traitement peut inclure des suppléments enzymatiques et des modifications diététiques."
}
},
{
"@type": "Question",
"name": "La thérapie génique est-elle une option ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "La thérapie génique est en recherche pour traiter certaines déficiences enzymatiques."
}
},
{
"@type": "Question",
"name": "Les médicaments peuvent-ils aider à gérer les symptômes ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des médicaments peuvent être prescrits pour gérer les symptômes associés."
}
},
{
"@type": "Question",
"name": "Y a-t-il des traitements expérimentaux en cours ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, plusieurs études cliniques explorent de nouveaux traitements pour ces troubles."
}
},
{
"@type": "Question",
"name": "Comment la nutrition influence-t-elle le traitement ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une nutrition adéquate peut améliorer la gestion des symptômes et le métabolisme."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir avec une déficience en phosphomutases ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des complications incluent des troubles métaboliques graves et des problèmes neurologiques."
}
},
{
"@type": "Question",
"name": "Les complications sont-elles réversibles ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines complications peuvent être gérées, mais d'autres peuvent être permanentes."
}
},
{
"@type": "Question",
"name": "Comment les complications affectent-elles la qualité de vie ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications peuvent réduire la qualité de vie en limitant les activités quotidiennes."
}
},
{
"@type": "Question",
"name": "Y a-t-il des risques de complications à long terme ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des risques de complications à long terme existent, nécessitant un suivi médical."
}
},
{
"@type": "Question",
"name": "Les complications peuvent-elles être prévenues ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines complications peuvent être évitées par un traitement précoce et un suivi régulier."
}
},
{
"@type": "Question",
"name": "Quels sont les facteurs de risque pour les troubles des phosphomutases ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les antécédents familiaux et certaines mutations génétiques augmentent le risque."
}
},
{
"@type": "Question",
"name": "L'environnement joue-t-il un rôle dans ces troubles ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des facteurs environnementaux peuvent influencer l'expression des gènes liés aux phosphomutases."
}
},
{
"@type": "Question",
"name": "Les habitudes alimentaires influencent-elles le risque ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une mauvaise alimentation peut exacerber les symptômes et augmenter le risque de complications."
}
},
{
"@type": "Question",
"name": "Y a-t-il des groupes à risque spécifique ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les personnes avec des antécédents familiaux de troubles métaboliques sont à risque accru."
}
},
{
"@type": "Question",
"name": "Le stress peut-il affecter le risque de troubles ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le stress peut aggraver les symptômes et influencer le métabolisme."
}
}
]
}
]
}
Community health is key for improving Reproductive, Maternal, Newborn, Child, and Adolescent Health and Nutrition (RMNCAH-N). However, how community health supports integrated RMNCAH-N service deliver...
We examined how six francophone West African countries (Burkina Faso, Côte d'Ivoire, Guinea, Mali, Niger, and Senegal) support community health through the Global Financing Facility for Women, Childre...
We conducted a content analysis on Investment Cases and Project Appraisal Documents from selected countries, and set out the scope of the analysis and the key search terms. We applied an iterative hyb...
In country documents, there is a commitment to community health, with significant attention paid to various cadres of community health workers (CHWs) who undertake a range of preventive, promotive and...
There is an opportunity to better prioritize and streamline community health interventions, including integrating them into health system planning and budgeting, to fully harness their potential to im...
Emerging evidence in women supports the notion that pregnancy may reset disease resistance, thereby providing protection against subsequent adverse health outcomes, but this hypothesis has not been ad...
Adolescents and young people (AYP) aged 15-24 years have the least access to facility-based sexual and reproductive health (SRH) services, including HIV services. The Yathu-Yathu cluster-randomized tr...
Yathu Yathu was a CRT conducted in two communities in Lusaka, Zambia, with 10 intervention and 10 control zones. AYP in all zones were offered prevention points cards (PPC), which incentivized and tra...
161 cases and 160 controls consented to participate in the study. Participants aged 20-24 years (adjOR 1.99, 95%CI 1.26-3.12, p = 0.003), who were educated up to college level (adjOR 8.47,95%CI 2.08-3...
Despite Yathu Yathu services being community-based and more accessible compared to health facilities, we found age, education and employment were associated with not attending hubs. Strategies are nee...
Ecotoxicology studies were performed in the earthworm Eisenia fetida with four different synthetic amorphous silica (SAS) (SYLOID® AL-1 FP, SYLOID® MX 107, LUDOX® P T-40F, and HDK® N20) mixed into art...
An understanding of the associations between midregion fat depots and systemic hormone levels will be crucial for developing health-promotion messages aimed at overweight or obese women. However, rela...
A total of 250 eligible overweight or obese women scheduled to undergo laparoscopic sleeve gastrectomy (LSG) from a single center were retrospectively included in this study. Computed tomography (CT) ...
Positive correlations were detected for prolactin (PRL) with total fat area (TFA) [β=0.045; P=0.029; 95% confidence interval (CI): 0.004-0.085] and subcutaneous fat area (SFA) (β=0.066; P=0.023; 95% C...
There exist certain associations between some reproduction-related pituitary and ovarian hormones and fat areas. Our findings provide new insights into the associations between midregion fat depots an...
Antenatal care is one of the best strategies for maternal and neonatal mortality reduction. There is a paucity of evidence on the mean number of ANC visits and associated factors in Sub-Saharan Africa...
A total of 256,425 weighted numbers of women who gave birth five years before the survey were included. We used STATA version 14 for data management and analysis. A multilevel negative binomial regres...
The mean number of ANC visits among women who gave birth five years before the survey in SSA was 3.83 (95% CI = 3.82, 3.84) Individual-level factors such as being aged 36-49 years (AIRR = 1.20, 95% CI...
The mean number of ANC visits in SSA approximates the minimum recommended number of ANC visits by the World Health Organization. Women's educational status, women's age, media exposure, parity, planne...
Hypocalcaemia is an important disorder associated with an increased risk of metabolic diseases, and many studies have been going on for decades. This study investigated the effects of anionic and zeol...
The prevalence of porcine reproductive and respiratory syndrome virus 1 (PRRSV1) isolates has continued to increase in Chinese swine herds in recent years. However, no effective control strategy is av...
Combination prevention interventions, when integrated with community-based support, have been shown to be particularly beneficial to adolescent and young peoples' sexual and reproductive health. Betwe...
The process evaluation was conducted in accordance with the Medical Research Council guidelines using quantitative and qualitative approaches. Self-completed surveys and clinic and programmatic data w...
The intervention was feasible and acceptable to young people and intervention implementing teams. In particular, the STI testing and SRH components of the intervention were popular. The main challenge...
The results demonstrated that peer-led community-based care that integrates SRH services with HIV is a versatile model to decentralise health and social care. The family could be a platform to target ...
Women of reproductive age (WRA) in developing countries are often at risk of micronutrient deficiencies due to inadequate intakes and excessive losses....
The purpose of this trial is to assess the effectiveness of United Nations International Multiple Micronutrient Antenatal Preparation-Multiple Micronutrient Supplements (UNIMMAP-MMS) versus iron-folic...
Three parallel groups of WRA will participate in a community-based, individually randomized, double-blinded, placebo-controlled superiority trial. After consent, the sample of 375 mildly or moderately...
The World Health Organization (WHO) added UNIMMAP-MMS to its essential medicine lists in 2021 but recommended rigorous study. Several factors in addition to inadequate intakes of iron and folic acid c...
ClinicalTrials.gov NCT05682261. Registered on January 12, 2023....